Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP.
about
Advances in Diagnosis and Treatments for Immune ThrombocytopeniaImmune thrombocytopeniaRapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesB cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia.Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain.Helicobacter pylori infection in Mongolian gerbils does not initiate hematological diseasesCD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.Mouse Models for Immune-Mediated Platelet Destruction or Immune Thrombocytopenia (ITP).Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia.Genome-wide association mapping of acute lung injury in neonatal inbred miceIVIG regulates the survival of human but not mouse neutrophils.Optimal attenuation of experimental autoimmune encephalomyelitis by intravenous immunoglobulin requires an intact interleukin-11 receptor.Determinants of host susceptibility to murine respiratory syncytial virus (RSV) disease identify a role for the innate immunity scavenger receptor MARCO gene in human infantsProphylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D.Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patientsIntravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.Role of FcγRIIIA (CD16) in IVIg-mediated anti-inflammatory function.Review: intravenous immunoglobulin and B cells: when the product regulates the producer.Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye.Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.IVIG-mediated effector functions in autoimmune and inflammatory diseases.Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations.Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?On the appropriate use and interpretation of animal models in transfusion medicine research.Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin.Unraveling the IVIG mystique.Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patientsIVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist
P2860
Q26738630-00C8F96C-8BC4-432C-9204-2D37595E8ED0Q26830918-802B4F24-BFC6-495E-9C52-484771566C9EQ26864907-DD7621A6-D729-42EC-8678-FF31A117BCF5Q28069362-AD627BD4-EDFE-47E6-857E-12D783B88D49Q33403107-D498701F-1E64-4173-977B-7932801C4CCFQ33409032-6EA7423E-222B-4009-A7FB-4822C37C7FAEQ33415298-884D009C-D47D-400A-A138-F4CC68A860A9Q33417717-054AD826-CD7B-4D0E-9D67-E068DB1AD3FEQ33419269-F9B51F71-B9B9-48CA-A56F-B3B7CA78D139Q33431172-4EA97213-F458-42E2-B3D0-D296B311A945Q33438855-E650A2C4-5D3C-475E-9075-6733E4DAE3BEQ33613229-19177476-7943-4176-AAEA-4797E8458C41Q33683531-D53E9FB8-4DF5-4542-A4B9-08B13169FEBCQ33981829-06D13E42-950D-43E9-97A0-B6D750B395B3Q34678450-9401436B-E59A-407C-8485-E5B973F2E4A0Q35262648-DC0B8A5E-BA6D-40E8-B325-8FE60500A8AEQ36484438-A90ADE12-8E26-4DD3-9D1C-C58D0AE91453Q37732919-7CCD3FC1-578F-4D3A-A01A-034914938D4BQ38133405-AF3E0F37-B79B-4169-8B3B-8997F6917275Q38204293-84CDB4DA-0E43-44EB-B66F-96D342B33AF8Q38258905-76F04527-578D-4772-A5AC-15910FDC7434Q38344833-C02EC76B-8FD6-4176-AC89-76C336F6D568Q38478867-8924E39E-8D97-4200-A956-679B44B6AA29Q38547198-A2F7793B-4C96-4EE2-960C-404BFDF94C48Q38615353-BCB2110F-0E5F-4F86-A2CD-76620293BB7AQ38699812-EDDFA045-D7D0-40F8-8EA0-08CC896AFBB2Q38820288-5C876E0D-B21E-4F4D-8788-41ECB67FE494Q39361301-5BECB052-FBF0-4E26-BA22-332F76CBBE62Q42375731-FC596FD5-726A-4B85-BB44-7D6D3D4470B9Q43699801-7F687E32-3E6D-4B26-8725-8895A27C65D9Q45422267-53EBD598-5C64-4264-B9E8-BEB7A824E919Q48304490-8BFFEBBE-0D82-4044-8DE1-B4EF7A7DEA68Q50193260-CBB067DA-D28D-4235-BAC9-4A4D22A7BEC0Q58861212-44A31F32-65C6-45C4-95BA-00DA0D203B47Q58861220-C9624DF7-D532-4C63-B75C-B333A0AD9F76
P2860
Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Mouse background and IVIG dosa ...... lioration of experimental ITP.
@ast
Mouse background and IVIG dosa ...... lioration of experimental ITP.
@en
type
label
Mouse background and IVIG dosa ...... lioration of experimental ITP.
@ast
Mouse background and IVIG dosa ...... lioration of experimental ITP.
@en
prefLabel
Mouse background and IVIG dosa ...... lioration of experimental ITP.
@ast
Mouse background and IVIG dosa ...... lioration of experimental ITP.
@en
P2093
P1433
P1476
Mouse background and IVIG dosa ...... lioration of experimental ITP.
@en
P2093
Danila Leontyev
Donald R Branch
Yulia Katsman
P304
P356
10.1182/BLOOD-2012-03-415695
P407
P577
2012-04-16T00:00:00Z